mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Ipsen and Debiopharm announce launch of Decapeptyl

Posted on 08/02/2010 in Pharmaceutical Company Product News

Ipsen and Debiopharm have revealed that a 22.5 mg six-month sustained-release formulation of Decapeptyl (triptorelin embonate1) has been launched in France.

The drug, which is indicated for the treatment of locally advanced or metastatic hormone-dependent prostate cancer, is set to be launched in Germany and Portugal in the future and is currently awaiting approval for other nations, such as the UK, Ireland, Italy and Romania.

Marketing authorisation for Decapeptyl was granted in November 2009 by French regulatory authorities.

The compound was developed by Debiopharm, which licensed the marketing rights to Ipsen for all territories where the firm commercialises triptorelin.

Ipsen and Debiopharm announced the successful completion of the European decentralised registration procedure for nine countries in October 2009.

Earlier this month, Ipsen unveiled its financial results for 2009, revealing a 7.6 per cent growth in drug sales during the period.

Consolidated group sales stood at 1,032.8 million euros (900,000 pounds) for the whole of 2009 - a year-on-year increase of 6.8 per cent.

Other news stories from 08/02/2010

Read more in the Zenopa News Archive

How this news is generated

Nikki
Account Manager
for this opportunity

01494 818032
(Mon to Fri 0830 to 1800 hours)
nikki@zenopa.com

Latest News

Ipsen licenses therapeutics to Rhythm

Ipsen gout treatment launches in Europe

Ipsen and Debiopharm announce launch of Decapeptyl

Ipsen reveals financial outcomes for 2009

Ipsen enters into partnership with Inspiration Biopharmaceuticals

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use